REGN vs SAM · P/E 14, rev $14.34B vs rev $2.01B
Regeneron Pharmaceuticals Inc (REGN) versus Boston Beer Company Inc (SAM) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Boston Beer Company Inc (SAM) is a beverages - brewers company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SAM revenue for 2024-12-28 was $2.01B. Net income was $59.7M. Revenue was up 0.2% from 2023-12-30 to 2024-12-28. SAM currently screens at market cap $1.79B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SAM currently screens at market cap $1.79B.
Not investment advice. Open the REGN and SAM stock pages for the full models.
Not investment advice.